Gilead Sciences, Inc (GILD34) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Gilead Sciences, Inc BRL 39.07, price BRL 63.06, upside -38.0%, quality 78 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.
How to read this chart
60‑month range R$10.44 – R$271.58 · fair‑value band R$27.32 – R$52.62 · the R$63.06 price screens above the R$39.07 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 28, 2026.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
Show more
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Stock analysis
Gilead Sciences, Inc (GILD34) currently trades at R$63.06, while our model-based Fair Value estimate is R$39.07, 38.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of R$51.64 per share, and 1 of the 24 models we run sit above the R$63.06 price.
Bear case: the Asset-Based group reads lowest at R$5.44, and 23 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: R$27.32 (bear) to R$52.62 (bull), the price of R$63.06 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 78/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Gilead Sciences, Inc reported revenue of $29.4B in FY2025 versus $27.3B in FY2021, a compound +1.9%/yr. Reported net income was $8.5B in FY2025, compounding +8.1%/yr from FY2021.
Key figures
Market cap R$838B (≈ $160B) · P/E ratio 17.7 · P/S ratio 5.13 · EPS (TTM) R$19.03 · Dividend yield 1.0% · Net margin 28.9% · Return on equity 43.4% · Return on assets (EBIT) 11.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).
What moves the price
The share trades about 5% below its 52-week high and 39% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −38%, GILD34 screens richer than that median.
Fair Value models
Bear R$27.32Fair Value R$39.07Bull R$52.62
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$11.98 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.75/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+2.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+24.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+23.0%
Dividend (yield on the price)1.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 34%
2025 sits 86% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Gilead Sciences, Inc (GILD34) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of R$39.07 versus a price of R$63.06, about −38% upside (overvalued).
What is the fair value of GILD34?
Our model-based fair value for Gilead Sciences, Inc is R$39.07 (as of Sep 28, 2026), built from audited fundamentals. The current price: R$63.06.
What is the quality score of GILD34?
Gilead Sciences, Inc has a Quality Score of 78/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gilead Sciences, Inc (GILD34)?
Our model-based price target is the fair value of R$39.07 (as of Sep 28, 2026) from 24 valuation models. Cautious scenario R$27.32, optimistic scenario R$52.62. It is a calculation from audited fundamentals, not an analyst target.
What is the Gilead Sciences, Inc stock forecast for 2026?
Our models put fair value at R$39.07, about −38% upside versus a price of R$63.06 (overvalued). Cautious scenario R$27.32, optimistic scenario R$52.62. The calculation is refreshed regularly with new filings.
What is the revenue of Gilead Sciences, Inc (GILD34)?
Gilead Sciences, Inc reported trailing-twelve-month revenue of about $29.7B (latest available figure, as of Sep 28, 2026).
Does Gilead Sciences, Inc pay a dividend?
Gilead Sciences, Inc currently shows a dividend yield of about 0.95% relative to its recent price (as of Sep 28, 2026).
What is the intrinsic value of Gilead Sciences, Inc (GILD34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gilead Sciences, Inc it is R$39.07 per share (as of Sep 28, 2026), against a price of R$63.06. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Gilead Sciences, Inc stock overvalued or undervalued in 2026?
As of Sep 28, 2026, GILD34 trades above its calculated fair value: price R$63.06, fair value R$39.07, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GILD34?
No. The price is what the market pays today (R$63.06); the fair value is what the company's own numbers justify (R$39.07). For Gilead Sciences, Inc the two are R$23.99 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gilead Sciences, Inc worth?
The market values Gilead Sciences, Inc at about R$838B (market capitalisation, as of Sep 28, 2026). Per share that is R$63.06; our models calculate a fair value of R$39.07 per share.
What do the bullish and bearish scenarios say about GILD34?
Our models span a range for Gilead Sciences, Inc: cautious scenario R$27.32, base R$39.07, optimistic R$52.62 per share (as of Sep 28, 2026, price R$63.06). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is GILD34 from its 52-week high?
Gilead Sciences, Inc trades at R$63.06, about 5% below its 52-week high of R$66.29 and 39% above the low of R$45.31 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of R$39.07 is for.
Which stocks are comparable to Gilead Sciences, Inc?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gilead Sciences, Inc stock attractive at the current price?
The data as of Sep 28, 2026: price R$63.06, calculated fair value R$39.07 (−38%), Quality Score 78/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GILD34 calculated?
We run Gilead Sciences, Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$39.07, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Gilead Sciences, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gilead Sciences, Inc (GILD34)?
The closing price on Oct 2, 2026 was R$63.06. Our model-based fair value is R$39.07, about −38% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gilead Sciences, Inc right now?
A high-quality business (quality 78/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (R$52.62). The favourable scenario is already priced in. A fairly wide model range (R$27.32 to R$52.62) leaves room in how you read the outcome.
Key figures of Gilead Sciences, Inc
How large is the market capitalisation of Gilead Sciences, Inc (GILD34)?
The market capitalisation of Gilead Sciences, Inc is R$838B (≈ $160B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Gilead Sciences, Inc (GILD34)?
The price-to-earnings ratio of Gilead Sciences, Inc is 17.7 (as of Jul 16, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Gilead Sciences, Inc (GILD34)?
The price-to-sales ratio of Gilead Sciences, Inc is 5.13 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gilead Sciences, Inc (GILD34)?
Earnings per share at Gilead Sciences, Inc are R$19.03 (price ÷ EPS = P/E 17.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Gilead Sciences, Inc (GILD34)?
The dividend yield of Gilead Sciences, Inc is 1.0% (payout 3.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Gilead Sciences, Inc (GILD34)?
The net margin of Gilead Sciences, Inc is 28.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gilead Sciences, Inc (GILD34)?
The return on equity (ROE) of Gilead Sciences, Inc is 43.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gilead Sciences, Inc (GILD34)?
On an EBIT basis the return on assets of Gilead Sciences, Inc is 11.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gilead Sciences, Inc (GILD34)?
The operating margin of Gilead Sciences, Inc is 39.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gilead Sciences, Inc (GILD34)?
Revenue at Gilead Sciences, Inc is growing +4.4% versus a year earlier (3y avg +2.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Gilead Sciences, Inc (GILD34)?
Earnings per share at Gilead Sciences, Inc are growing +54.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Gilead Sciences, Inc (GILD34) generate?
The free cash flow of Gilead Sciences, Inc is $9.5B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Gilead Sciences, Inc (GILD34) carry?
The net debt of Gilead Sciences, Inc is $17.4B (fiscal year 2025, ≈ 1.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
